Document Detail


Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia.
MedLine Citation:
PMID:  20446955     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Anti-tumour necrosis factor (TNF) therapy is an effective but expensive option for treating inflammatory bowel disease (IBD). Its use is generally reserved for patients with severe refractory disease, often involving long-term administration. Anti-TNF therapy has the potential to be associated with various adverse effects, such as infection, malignancy and immunogenicity. Clinicians and patients should be familiar with these possibilities and adopt appropriate precautions prior to and during treatment to minimize risk. Guidelines have been developed for Australian prescribers intending to use anti-TNF therapy in IBD by a Working Party commissioned by IBD-Australia, a Special Interest Group affiliated with the Gastroenterology Society of Australia.
Authors:
W Connell; J M Andrews; S Brown; M Sparrow
Related Documents :
25228995 - Environmental changes, microbiota, and allergic diseases.
16730305 - The role of radiation therapy in benign diseases.
1479105 - Photodynamic therapy in the treatment of bowen's disease.
7732175 - Treatment of resistant takayasu's arteritis.
9894165 - Progressive pseudorheumatoid dysplasia: report of a patient with symptoms present at bi...
19276545 - Cryptococcal meningitis misdiagnosed as alzheimer's disease: complete neurological and ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Internal medicine journal     Volume:  40     ISSN:  1445-5994     ISO Abbreviation:  Intern Med J     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-05-07     Completed Date:  2011-01-18     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  101092952     Medline TA:  Intern Med J     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  139-49     Citation Subset:  IM    
Affiliation:
St Vincent's Hospital, Melbourne, Victoria, Australia. william.connell@svhm.org.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Advisory Committees / standards*
Antibodies, Monoclonal / pharmacology,  therapeutic use*
Antibodies, Monoclonal, Humanized
Australia / epidemiology
Humans
Inflammatory Bowel Diseases / drug therapy*,  epidemiology*,  immunology
Practice Guidelines as Topic / standards*
Societies, Medical / standards
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Tumor Necrosis Factor-alpha; 0/infliximab; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carotid intima-media thickness in subclinical hypothyroidism.
Next Document:  Phaeochromocytoma-associated critical peripheral ischaemia.